Search

Displaying results 7381 - 7390 of 10000 in total
  1. Drug

    Streptococcus pneumoniae type 8 capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB16713
    ApprovedInvestigational

    The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate.

  2. Drug

    Streptococcus pneumoniae type 11A capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB16715
    ApprovedInvestigational

    The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate.

  3. Drug

    Streptococcus pneumoniae type 15A capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB19343
    ApprovedInvestigational

    The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate.

  4. Drug

    Streptococcus pneumoniae type 17F capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB19346
    ApprovedInvestigational

    The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate.

  5. Drug

    Streptococcus pneumoniae type 20A capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB19347
    ApprovedInvestigational

    The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate.

  6. Drug

    AG0301-COVID19

    go.drugbank.com/drugs/DB15856
    Investigational

    The candidate is a plasmid DNA vaccine developed using an intradermal gene transfer method targeting the SARS-CoV-2 spike protein. … On September 8, 2020 AnGes announced collaboration with Brickell Biotech, Inc. following completion of Phase 1/2 clinical studies (NCT04463472).

  7. Drug

    Budigalimab

    go.drugbank.com/drugs/DB16668
    Investigational

    With IV Modified FOLFIRINOX (Mffx) With or Without IV Budigalimab Compared to Mffx in Adult Participants With Untreated Pancreatic Cancer Metastasis). … Budigalimab is under investigation in clinical trial NCT04807972 (Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 Is Administered in Combination

  8. Drug

    PF-06282999

    go.drugbank.com/drugs/DB11683
    Investigational

    Pf 06282999 is under investigation in clinical trial NCT01626976 (A Study To Assess The Safety, Tolerability And Pharmacokinetics Of PF-06282999 Administered Orally In Healthy Adult Subjects).

  9. Drug

    SB-649868

    go.drugbank.com/drugs/DB14822
    Investigational

    SB-649868 is under investigation in clinical trial NCT01030939 (Study to Investigate Safety, Tolerability, Pharmacokinetics and Cardiac Function After Repeat Doses of SB-649868 in Healthy-volunteers).

  10. Drug

    Pegvorhyaluronidase alfa

    go.drugbank.com/drugs/DB14912
    Investigational

    Pegvorhyaluronidase alfa is under investigation in clinical trial NCT02241187 (Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection

    Synonyms: ALFA, SUBSTITUTED ON N6 OF AN AVERAGE OF 4 TO, HUMAN HYALURONIDASE PH-20 (HYALURONOGLUCOSAMINIDASE PH-20, SPERM ADHESION MOLECULE 1, EC 3.2.1.35) PRECURSOR-(36-482)-PEPTIDE (MATURE (1-447)-PEPTIDE), PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS, GLYCOFORM